32
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      BAP1 regulates IP3R3-mediated Ca 2+ flux to mitochondria suppressing cell transformation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BRCA1-associated protein 1 (BAP1) is a potent tumor suppressor gene that modulates environmental carcinogenesis 1- 3 . All carriers of inherited heterozygous germline BAP1 inactivating mutations ( BAP1 +/-) developed one and often several BAP1 -/- malignancies in their lifetime 4 , mostly malignant mesothelioma (MM), uveal melanoma (UVM) 2, 5 , etc 6- 10 . Moreover, BAP1 acquired biallelic mutations are frequent in human cancers 8, 11- 14 . BAP1 tumor suppressor activity has been attributed to its nuclear localization where BAP1 helps maintaining genome integrity 15- 17 . The possible activity of BAP1 in the cytoplasm was unknown. Cells with reduced levels of BAP1 exhibit chromosomal abnormalities and decreased DNA repair by homologous recombination 18 , indicating that BAP1 dosage is critical. Cells with extensive DNA damage should die and not grow into malignancies. We discovered that BAP1 localizes at the endoplasmic reticulum (ER). Here BAP1 binds, deubiquitylates and stabilizes type-3 inositol-1,4,5-trisphosphate-receptor (IP3R3), modulating calcium (Ca 2+) release from the ER into the cytosol and mitochondria, promoting apoptosis. Reduced levels of BAP1 in BAP1 +/- carriers caused reduction of both IP3R3 levels and Ca 2+ flux, preventing BAP1 +/- cells that had accumulated DNA damage from executing apoptosis. A higher fraction of cells exposed to either ionizing or ultraviolet radiation, or to asbestos, survived genotoxic stress resulting in a higher rate of cellular transformation. We propose that the high incidence of cancers in BAP1 +/- carriers results from the combined reduced nuclear and cytoplasmic BAP1 activities. Our data provide a mechanistic rationale for the powerful ability of BAP1 to regulate gene-environment interaction.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Calcium signaling.

          Calcium ions (Ca(2+)) impact nearly every aspect of cellular life. This review examines the principles of Ca(2+) signaling, from changes in protein conformations driven by Ca(2+) to the mechanisms that control Ca(2+) levels in the cytoplasm and organelles. Also discussed is the highly localized nature of Ca(2+)-mediated signal transduction and its specific roles in excitability, exocytosis, motility, apoptosis, and transcription.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            BAP1 loss defines a new class of renal cell carcinoma

            The molecular pathogenesis of renal cell carcinoma (RCC) is poorly understood. Whole-genome and exome sequencing followed by innovative tumorgraft analyses (to accurately determine mutant allele ratios) identified several putative two-hit tumor suppressor genes including BAP1. BAP1, a nuclear deubiquitinase, is inactivated in 15% of clear-cell RCCs. BAP1 cofractionates with and binds to HCF-1 in tumorgrafts. Mutations disrupting the HCF-1 binding motif impair BAP1-mediated suppression of cell proliferation, but not H2AK119ub1 deubiquitination. BAP1 loss sensitizes RCC cells in vitro to genotoxic stress. Interestingly, BAP1 and PBRM1 mutations anticorrelate in tumors (P=3×10−5), and combined loss of BAP1 and PBRM1 in a few RCCs was associated with rhabdoid features (q=0.0007). BAP1 and PBRM1 regulate seemingly different gene expression programs, and BAP1 loss was associated with high tumor grade (q=0.0005). Our results establish the foundation for an integrated pathological and molecular genetic classification of RCC, paving the way for subtype-specific treatments exploiting genetic vulnerabilities.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.

              Through exomic sequencing of 32 intrahepatic cholangiocarcinomas, we discovered frequent inactivating mutations in multiple chromatin-remodeling genes (including BAP1, ARID1A and PBRM1), and mutation in one of these genes occurred in almost half of the carcinomas sequenced. We also identified frequent mutations at previously reported hotspots in the IDH1 and IDH2 genes encoding metabolic enzymes in intrahepatic cholangiocarcinomas. In contrast, TP53 was the most frequently altered gene in a series of nine gallbladder carcinomas. These discoveries highlight the key role of dysregulated chromatin remodeling in intrahepatic cholangiocarcinomas.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                31 July 2017
                14 June 2017
                22 June 2017
                14 December 2017
                : 546
                : 7659
                : 549-553
                Affiliations
                [1 ]University of Hawaii Cancer Center, University of Hawaii, Honolulu, Hawaii, USA
                [2 ]Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
                [3 ]Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
                [4 ]Experimental Imaging Center, San Raffaele Scientific Institute Milano, Italy
                [5 ]Department of Experimental Medicine, University of Genova, Genova, Italy
                [6 ]Cancer Center, New York University, New York, New York 10065, USA
                [7 ]Maisonneuve-Rosemont Hospital Research Center, Department of Medicine, University of Montréal, Montréal, Quebec, Canada
                Author notes
                Correspondence and requests for material should be addressed to M. C. ( MCarbone@ 123456cc.hawaii.edu ), Paolo Pinton ( paolo.pinton@ 123456unife.it ) or Haining Yang ( HYang@ 123456cc.hawaii.edu )
                [*]

                Co-corresponding authors

                Article
                NIHMS872466
                10.1038/nature22798
                5581194
                28614305
                d27b1784-9cc3-45a9-9136-9097872f9a3b

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article